Literature DB >> 15612830

Measurement of health-related QOL in diabetes mellitus.

Ken Watkins1, Cathleen M Connell.   

Abstract

A number of health-related QOL (HR-QOL) measures specifically designed for people with diabetes mellitus have appeared in the literature. This article provides a selective review of 12 measures that address this important construct. For each included study, a description of the measure and its development phase is provided, followed by discussion of sampling, reliability, validity and appropriateness for selected populations. Measures designed to investigate broad and specific conceptualisations of diabetes-specific QOL are included. For research in which a broad conceptualisation of diabetes-specific QOL is appropriate, the following measures are recommended: Diabetes-39, Diabetes Care Profile (DCP), Diabetes Impact Management Scales (DIMS), Diabetes Quality of Life (DQOL) and the Diabetes-Specific Quality of Life Scale (DSQOLS). For investigation of one or more specific aspects of diabetes-specific QOL, other measures may also be appropriate: single-scale questionnaires such as the Appraisal of Diabetes Scale (ADS) [stressful impact], Audit of Diabetes-Dependent Quality of Life (ADDQoL) [life without diabetes] and the Problem Areas in Diabetes scale (PAID) [diabetes-related distress]; the Diabetes Health Profile (DHP) which focuses on diabetes-related distress, activity and eating behaviour; the Questionnaire on Stress in Patients with Diabetes-Revised (QSD-R) which has a primary focus on diabetes-related distress; and the Well-Being Enquiry for Diabetics (WED) which is primarily concerned with the perceptions of patients with diabetes in relation to mental health. Researchers selecting a diabetes-specific QOL measure should also carefully consider the conceptual underpinnings of the available instruments, as there is little uniformity in the definition and conceptualisation of HR-QOL. Based upon participants involved in questionnaire development and validation studies, those questionnaires that appear to be most appropriate for use with a variety of patient populations include the Diabetes-39, DIMS, Diabetes Quality of Life Clinical Trial Questionnaire-Revised (DQLCTQ-R), PAID and the QSD-R. The DCP and DHP appear to be especially relevant measures of HR-QOL for patients with type 2 diabetes, while the DQOL, DSQOLS and WED have clear emphases on concerns of individuals with type 1 diabetes. The length of the DQLCTQ-R may raise concerns about its use among some populations (e.g. older adults). Recommendations for future research include: (i) increasing the diversity of samples used to develop and evaluate existing and new measures in terms of race/ethnicity, age and gender; (ii) examination of the causal relationship between diabetes self-management and QOL using longitudinal designs; (iii) increasing emphasis on the positive aspects of successful chronic illness self-management; and (iv) use of HR-QOL measures to inform empowering relationships between physicians and patients.

Entities:  

Mesh:

Year:  2004        PMID: 15612830     DOI: 10.2165/00019053-200422170-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  33 in total

1.  Reliability and validity of the appraisal of diabetes scale.

Authors:  M P Carey; R S Jorgensen; R S Weinstock; R P Sprafkin; L J Lantinga; C L Carnrike; M T Baker; A W Meisler
Journal:  J Behav Med       Date:  1991-02

2.  Validation of a diabetes-specific quality-of-life scale for patients with type 1 diabetes.

Authors:  U Bott; I Mühlhauser; H Overmann; M Berger
Journal:  Diabetes Care       Date:  1998-05       Impact factor: 19.112

3.  Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). The DCCT Research Group.

Authors: 
Journal:  Diabetes Care       Date:  1988-10       Impact factor: 19.112

4.  Development and validation of the Diabetes Care Profile.

Authors:  J T Fitzgerald; W K Davis; C M Connell; G E Hess; M M Funnell; R G Hiss
Journal:  Eval Health Prof       Date:  1996-06       Impact factor: 2.651

5.  The influence of treatment modality and ethnicity on attitudes in type 2 diabetes.

Authors:  J T Fitzgerald; L D Gruppen; R M Anderson; M M Funnell; S J Jacober; G Grunberger; L C Aman
Journal:  Diabetes Care       Date:  2000-03       Impact factor: 19.112

6.  Assessment of diabetes-related distress.

Authors:  W H Polonsky; B J Anderson; P A Lohrer; G Welch; A M Jacobson; J E Aponte; C E Schwartz
Journal:  Diabetes Care       Date:  1995-06       Impact factor: 19.112

7.  The validity and reliability of the Diabetes Health Profile (DHP) in NIDDM patients referred for insulin therapy.

Authors:  P Goddijn; H Bilo; K Meadows; K Groenier; E Feskens; B Meyboom-de Jong
Journal:  Qual Life Res       Date:  1996-08       Impact factor: 4.147

Review 8.  Diabetes and behavioral medicine: the second decade.

Authors:  Linda A Gonder-Frederick; Daniel J Cox; Lee M Ritterband
Journal:  J Consult Clin Psychol       Date:  2002-06

Review 9.  Responsiveness of the Problem Areas In Diabetes (PAID) questionnaire.

Authors:  G Welch; K Weinger; B Anderson; W H Polonsky
Journal:  Diabet Med       Date:  2003-01       Impact factor: 4.359

10.  Measurement of health status in diabetic patients. Diabetes impact measurement scales.

Authors:  G S Hammond; T T Aoki
Journal:  Diabetes Care       Date:  1992-04       Impact factor: 19.112

View more
  33 in total

1.  Development and Testing of the Insulin Treatment Experience Questionnaire (ITEQ).

Authors:  Jörn Moock; Franz Hessel; Diana Ziegeler; Thomas Kubiak; Thomas Kohlmann
Journal:  Patient       Date:  2010-03-01       Impact factor: 3.883

2.  The relationship between quality of life and swallowing in Parkinson's disease.

Authors:  Emily K Plowman-Prine; Christine M Sapienza; Michael S Okun; Stephenie L Pollock; Charles Jacobson; Sam S Wu; John C Rosenbek
Journal:  Mov Disord       Date:  2009-07-15       Impact factor: 10.338

Review 3.  Advancing Measurement of Diabetes at the Population Level.

Authors:  Mohammed K Ali; Karen R Siegel; Michael Laxy; Edward W Gregg
Journal:  Curr Diab Rep       Date:  2018-09-19       Impact factor: 4.810

Review 4.  Patient-reported assessments in diabetes care: clinical and research applications.

Authors:  Soren E Skovlund
Journal:  Curr Diab Rep       Date:  2005-04       Impact factor: 4.810

5.  Validity and reliability of the 19-item Audit of Diabetes-Dependent Quality of Life (ADDQoL-19) questionnaire in Chinese patients with type 2 diabetes mellitus in primary care.

Authors:  Colman S C Fung; Eric Y F Wan; Charlotte L Y Yu; Carlos K H Wong
Journal:  Qual Life Res       Date:  2016-03-15       Impact factor: 4.147

6.  Quality of life and patient-perceived difficulties in the treatment of type 2 diabetes.

Authors:  Orly Tamir; Julio Wainstein; Itamar Raz; Joshua Shemer; Anthony Heymann
Journal:  Rev Diabet Stud       Date:  2012-05-10

7.  Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications.

Authors:  Nick Kontodimopoulos; Evelina Pappa; Zinovia Chadjiapostolou; Eleni Arvanitaki; Angelos A Papadopoulos; Dimitris Niakas
Journal:  Eur J Health Econ       Date:  2010-12-05

8.  The quality of life of adults with type 2 diabetes in a hospital care clinic in Taiwan.

Authors:  Huey-Fen Wang; Mei Chang Yeh
Journal:  Qual Life Res       Date:  2012-04-19       Impact factor: 4.147

9.  Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience.

Authors:  Meryl Brod; Soren E Skovlund; Kim U Wittrup-Jensen
Journal:  Qual Life Res       Date:  2006-04       Impact factor: 4.147

10.  Hemoglobin A1c improvements and better diabetes-specific quality of life among participants completing diabetes self-management programs: a nested cohort study.

Authors:  Abhinav Khanna; Amber L Bush; J Michael Swint; Melissa Fleschler Peskin; Richard L Street; Aanand D Naik
Journal:  Health Qual Life Outcomes       Date:  2012-05-14       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.